FOXO LIFE™ to Begin Distribution Relationship with AmSuisse to Sell Life Insurance Designed to Keep You Alive™

MINNEAPOLIS--(BUSINESS WIRE)--
FOXO Technologies Inc.™ (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced that its insurance distribution subsidiary, FOXO LIFE™, has engaged AmSuisse, an insurance brokerage general agency with products and specialty programs throughout the United States, to sell Life Insurance Designed to Keep You Alive™.

This partnership will enable FOXO to expand its distribution footprint through AmSuisse’s rapidly growing sales network of over 3,000 agents across 48 states. In selling life insurance complete with a FOXO Longevity Report™, AmSuisse will add to its robust product portfolio, enhancing its ability to deliver comprehensive insurance solutions to clients.

“The addition of AmSuisse to FOXO LIFE’s distribution hierarchy will allow us to sell life insurance designed to keep you alive in new and expanded markets,” said Jim Grauel, Jr., Chief Distribution Officer of FOXO LIFE. “We are excited to have the AmSuisse team join FOXO LIFE and look forward to working together.”

“On behalf of the entire AmSuisse team, we are excited to introduce FOXO’s first-to-market, next-generation science to our independent agency partners across the United States. The fact that FOXO is putting this program into the hands of independent agents speaks volumes. The ability to empower clients with science-based information designed to help them live longer and better lives is a tremendous value proposition,” said Josh Hamann, CEO AmSuisse.

About FOXO Technologies Inc. (“FOXO”)

FOXO is a technology platform company focused on commercializing longevity science through products and services that serve the life insurance industry. FOXO's epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. FOXO seeks to modernize the life insurance industry by simplifying the consumer underwriting journey with saliva-based biomarkers and enhancing life insurance’s consumer value proposition with the FOXO Longevity Report. For more information about FOXO, visit www.foxotechnologies.com. For more information about FOXO LIFE, visit www.foxolife.com. For investor information and updates, visit https://foxotechnologies.com/investors/.

About AmSuisse

Established in 2013 and based in Katy, Texas, AmSuisse, Inc. has quickly risen to prominence as an insurance wholesaling leader. The company provides a broad range of insurance products, including many specialty programs for hard-to-place risks. Its founding goal is to provide its insurance agents and insurance broker partners with unrivaled service and selection. As a closed insurance wholesaler, it carefully selects the firms it works with, allowing it to deliver comprehensive insurance solutions, responsive service, and industry-leading support. AmSuisse believes in forging long-term business partnerships – a belief that has helped the company and its partners thrive in a competitive marketplace.

No Offer or Solicitation

This press release shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended or an exemption therefrom.

Forward-Looking Statements

This press release contains certain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Any statements other than statements of historical fact contained herein, including statements as to future results of operations and financial position, planned products and services, business strategy and plans, objectives of management for future operations of FOXO, market size and growth opportunities, competitive position and technological and market trends, are forward-looking statements. Such forward-looking statements include, but are not limited to, expectations, hopes, beliefs, intentions, plans, prospects, financial results or strategies regarding FOXO and the future held by management teams of FOXO, the future financial condition and performance of FOXO and the products and markets and expected future performance and market opportunities of FOXO. These forward-looking statements generally are identified by the words “anticipate,” “believe,” “could,” “expect,” “estimate,” “future,” “intend,” “strategy,” “may,” “might,” “strategy,” “opportunity,” “plan,” “possible,” “potential,” “project,” “predict,” “scales,” “representative of,” “valuation,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the risk that changes in the competitive and highly regulated industries in which FOXO operates, variations in operating performance across competitors, changes in laws and regulations affecting FOXO’s business, and changes in the combined capital structure, (ii) the ability to implement FOXO’s business plans, forecasts, and other expectations, (iii) potential inability of FOXO to establish or maintain relationships required to advance its goals or to achieve its commercialization and development plans, (iv) the enforceability of FOXO’s intellectual property, including its patents and the potential infringement on the intellectual property rights of others, and (v) the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry or in the markets or industries in which FOXO’s prospective customers operate, including the highly regulated insurance industry. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” filed with the SEC, and risks and uncertainties indicated in the Registration Statement, including those set forth under “Risk Factors” therein, and other documents filed or to be filed by FOXO from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FOXO assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.